ChemoCentryx reported encouraging progress in its clinical programs, notably positive Phase II results for CCX140 in diabetic nephropathy and advancements with CCX168 in rare autoimmune diseases. The company's strong cash position and upcoming milestones are likely to boost investor confidence and have a positive short-term impact on the stock.

[1]